Clinical Trials Logo

Reflux clinical trials

View clinical trials related to Reflux.

Filter by:

NCT ID: NCT05899491 Recruiting - GERD Clinical Trials

Role of ARMA in Selective Subset of Refractory GERD Patients.

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).

NCT ID: NCT05629143 Recruiting - Dyspepsia Clinical Trials

Primary carE PPi dEprescRibing Trial

PEPPER
Start date: May 12, 2023
Phase: Phase 4
Study type: Interventional

Proton pump inibitors (PPIs) is a class of medications that reduce the acid secretion in the stomach. These medications are very effective to relieve symptoms of acid reflux for a well-identified group of diseases and conditions. Over the years, a major rise in use of these drugs has occurred. Convincing analyses reveal that a large share of this use occurs outside regular indications, at inappropriately elevated doses and prolonged treatment durations. Moreover, there are increasing concerns regarding potential adverse effects and the high cost associated with improper PPI use. Guidelines propose to reduce chronic use of PPIs, but to date this has not generated a reduction in their application in clinical practice. One reason is the occurrence of a period of 2 weeks of increased acid secretion, with recurrence of symptoms, when these drugs are stopped after already a few weeks of usage (rebound effect). The best strategy to overcome this period of increased acid secretion and symptoms has not been established. The PEPPER study will evaluate two different strategies to overcome the period of increased secretion when trying to interrupt chronic proton pump inhibitor therapy. The investigators will compare the success of stopping PPIs when these strategies are implemented, compared to a classical strategy of stopping after intermittent PPI intake. The strategies under evaluation are a period of non-daily intake of proton pump inhibitors (on-demand) before stopping, or the use of alternative methods to control gastric acidity and reflux (so-called alginates). The investigators will evaluate the success rate of stopping chronic PPIs treatment with these approaches, compared to an interruption with intake of antacids. Patients will be followed up for 1 year after interruption of PPIs, and the level of symptom control, quality of life and healthcare costs will be evaluated at intervals. The study will be conducted in patients from primary care practices with chronic PPIs intake outside of the established disease indications.

NCT ID: NCT05162079 Not yet recruiting - Reflux Clinical Trials

Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy

ES-REFLUJO
Start date: March 1, 2022
Phase:
Study type: Observational

Introduction: Symptoms as heartburn and/or reflux is frequent consultations in community pharmacies, the characterization of them is crucial to provide appropriate patient counseling. To facilitate the assistance work of the community pharmacist and its coordination between different levels of care, a group of experts in Community Pharmacy, Primary Care, and Gastroenterology has recently worked on an algorithm to manage these symptoms. Objective: Analyse the epidemiological characteristics of patients who consult for symptoms of heartburn and/or reflux in Spanish community pharmacies, and evaluate the clinical and humanistic results of the protocolization of a Professional Pharmaceutical Service in said patients. Methods and analysis: The study design consists of a cross-sectional descriptive part, in which the clinical and sociodemographic characteristics of the patients who come to the community pharmacy will be evaluated for consultation derived from heartburn and/or reflux symptoms and a before-after descriptive study in which will evaluate the clinical and humanistic results in patients who come to the pharmacy after receiving pharmaceutical care.

NCT ID: NCT05041608 Enrolling by invitation - GERD Clinical Trials

Endoscopic Surgery for Gastrointestinal Disorders: A Multicenter Registry Study

Start date: February 17, 2021
Phase:
Study type: Observational

Currently, there is limited multi-center data on endoscopic surgery outcomes in western populations. Evaluation of these measurement would help the investigators compare them to conventional treatment modalities within current tertiary facilities; and consequently help the investigators identify appropriate treatment techniques and improve clinical management of patients at Rutgers RWJMS. The purpose of this retrospective registry study is to assess long term data on efficacy, safety and clinical outcome of Endoscopic Surgery within the gastrointestinal tract.

NCT ID: NCT04329000 Completed - Barrett Esophagus Clinical Trials

On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

Start date: February 2, 2010
Phase: N/A
Study type: Interventional

On-demand PPI therapy is feasible for the long-term treatment of patients with Barrett's esophagus.

NCT ID: NCT04006002 Terminated - Weight Loss Clinical Trials

Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this research study is to understand the mechanism of weight loss for weight loss procedures: that is Laparoscopic sleeve gastrectomy and Endoscopic sleeve Gastroplasty.

NCT ID: NCT03418350 Recruiting - Reflux Clinical Trials

The Role of Laryngopharyngeal Reflux in IPF

Start date: August 1, 2018
Phase:
Study type: Observational

The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT02988063 Withdrawn - Venous Leg Ulcer Clinical Trials

Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs

Start date: April 10, 2017
Phase: Phase 4
Study type: Interventional

This study evaluates the addition of polidocanol endovenous microfoam (PEM) to compression therapy to determine effectiveness in improving the healing of venous leg ulcers (VLUs) in adults with severe venous disease of the great saphenous vein (GSV). All participants will receive treatment with Varithena and compression therapy. The purpose of this study is to assess whether the use of PEM to correct superficial axial and varicose vein reflux is effective in improving healing of VLUs, over treatment with compression alone.

NCT ID: NCT02226484 Completed - Clinical trials for Gastroesophageal Reflux Disease

Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?

Start date: August 2014
Phase: Phase 1
Study type: Interventional

Purpose: 1. Determine if oral quercetin increases the expression of claudin-4 in the lining of the esophagus of patients with a diagnosis of gastroesophageal reflux disease (GERD); and 2. Determine whether the increase in claudin-4 by oral quercetin is accompanied by improvement in the barrier function and acid resistance of the lining of the esophagus of patients with a diagnosis of gastroesophageal reflux disease (GERD) If interested, participants will be consented and provided a questionnaire to complete as part of the study. Participants will undergo endoscopy for routine care and will have up to 8 esophageal biopsies (small tissue samples) taken for the research study. After endoscopy, participants will be contacted to begin a 6 week treatment period with study drug (Quercetin, taken twice daily). At the end of the 6 week period, participants will be scheduled to have blood drawn and to have a follow-up endoscopy with biopsies performed for the research study.

NCT ID: NCT02048449 Completed - Reflux Clinical Trials

Inter-rater Reliability of the Reflux Finding Score Among Gastroenterologists

Start date: January 2014
Phase: N/A
Study type: Observational

Title: Inter-rater reliability of the reflux finding score based on endoscopic laryngeal findings in the diagnosis of laryngopharyngeal reflux disease Participants: Voluntary participants after invitation among members (a total of about 40 gastroenterologists) of Gangwon Branch of Korean Society of Gastrointestinal Endoscopy and an otorhinolaryngologist Primary endpoint: Interrater reliability (Kappa coefficient) on the sum of reflux finding score more than 7 points between an otorhinolaryngologist and gastroenterologists (7 points means the cut-off value for the diagnosis of laryngopharyngeal reflux disease) Secondary endpoint: Agreement (%) on 8 items of reflux finding score for laryngopharygeal reflux among gastroenterologists